MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6375-6386

  Drayton, Ross M ^a   Peter, Stefan ^a   Myers, Katie ^a   Miah, Saiful ^a   Dudziec, Ewa ^a   Bryant, Helen E ^a   Catto, James W F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bladder cancer; FGFR3; FOXA1; Urothelial cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MESSENGER RNA; MICRORNA; MICRORNA 100; MICRORNA 485-5P; MICRORNA 486; MICRORNA 99A; SOMATOMEDIN BINDING PROTEIN 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXL1; TRANSCRIPTION FACTOR JUND; TRANSCRIPTION FACTOR SOX5; UNCLASSIFIED DRUG; FGFR3 PROTEIN, HUMAN; FOXA1 PROTEIN, HUMAN; MIRN100 MICRORNA, HUMAN; MIRN99 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BINDING SITE; BLADDER CANCER; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; UPREGULATION; BLADDER TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84906276694     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2221     Document Type: Article

References (46)

1. Chavan S, Bray F, Lortet-Teulent J, Goodman MM and Jemal A. International Variations in Bladder Cancer Incidence and Mortality. Eur Urol. 2014; 66(1):59-73.
2. Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim S, Stenzl A and Lotan Y. The economics of bladder cancer: Costs and considerations of caring for this disease. Eur Urol 2014; In Press: doi: 10.1016/j.eururo.2014.01.006.
3. Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN and Sonpavde G. A systemati review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012; 62(3):523-533.
4. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis. 2006; 27(3):361-373.
5. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M and Hamdy FC. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005; 23(13):2903-2910.
6. Linton KD, Rosario DJ, Thomas F, Rubin N, Goepel J, Abbod MF and Catto JW. Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. J Urol. 2013; 189(3):828-883.
7. Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, et al. Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol. 2012; 62(4):677-684.
8. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315-322
9. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS and Kim WY. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014; 111(8):3110-3115.
10. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, et al. Identification of distinct Basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014; 25(2):152-165.
11. van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC and Catto JW. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009; 55(3):650-657.
12. Catto JW, Miah S, Owen HC, Bryant H, Dudziec E, Larre S, Milo M, Rehman I, Rosario DJ, DiMartino E, Knowles MA, Meuth M, Harris AL and Hamdy FC. Distinct microRNA alterations characterize high and low grade bladder cancer. Cancer Res. 2009; 69(21):8472-8481.
13. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T and Visakorpi T. MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. Eur Urol. 2011; 59(5):671-681.
14. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R, de Rycke Y, Elvin P, Cassidy A, Spraggon C, Graham A, Southgate J, Asselain B, Allory Y, Abbou CC, Albertson DG, et al. Regional copy numberindependent deregulation of transcription in cancer. Nat Genet. 2006; 38(12):1386-1396.
15. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P and Waldman FM. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005; 11(11):4044-4055.
16. Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vogeli TA and Grimm MO. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res. 2004; 10(10):3410-3421.
17. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H and Orntoft TF. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003; 33(1):90-96.
18. Dyrskjot L, Zieger K, Kruhoffer M, Thykjaer T, Jensen JL, Primdahl H, Aziz N, Marcussen N, Moller K and Orntoft TF. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res. 2005; 11(11):4029-4036.
19. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F and Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006; 24(5):778-789.
20. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmstrom PU, de la Torre M, Wester K, Allory Y, Vordos D, Caillault A, Radvanyi F, Hein AM, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res. 2007; 13(12):3545-3551.
21. Forman JJ, Legesse-Miller A and Coller HA. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl Acad Sci U S A. 2008; 105(39):14879-14884.
22. Small EM, O'Rourke JR, Moresi V, Sutherland LB, McAnally J, Gerard RD, Richardson JA and Olson EN. Regulation of PI3-kinase/Akt signaling by muscleenriched microRNA-486. Proc Natl Acad Sci U S A. 2010; 107(9):4218-4223.
23. Williams SV, Hurst CD and Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013; 22(4):795-803.
24. Serandour AA, Avner S, Percevault F, Demay F, Bizot M, Lucchetti-Miganeh C, Barloy-Hubler F, Brown M, Lupien M, Metivier R, Salbert G and Eeckhoute J. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome research. 2011; 21(4):555-565.
25. Ung M, Ma X, Johnson KC, Christensen BC and Cheng C. Effect of estrogen receptor alpha binding on functional DNA methylation in breast cancer. Epigenetics: official journal of the DNA Methylation Society. 2014; 9(4).
26. Kerschner JL, Gosalia N, Leir SH and Harris A. Chromatin remodeling mediated by the FOXA1/A2 transcription factors activates expression in intestinal epithelial cells. Epigenetics: official journal of the DNA Methylation Society. 2014; 9(4).
27. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS and Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008; 132(6):958-970.
28. Dudziec E, Gogol-Doring A, Cookson V, Chen W and Catto J. Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells. PloS one. 2012; 7(3):e32750.
29. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, Hamdy FC and Catto JW. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007; 13(7):2046-2053.
30. Motallebipour M, Ameur A, Reddy Bysani MS, Patra K, Wallerman O, Mangion J, Barker MA, McKernan KJ, Komorowski J and Wadelius C. Differential binding and co-binding pattern of FOXA1 and FOXA3 and their relation to H3K4me3 in HepG2 cells revealed by ChIP-seq. Genome biology. 2009; 10(11):R129.
31. Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, Mansson W, Fioretos T and Hoglund M. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006; 25(18):2685-2696.
32. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ and Bae SC. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Molecular cancer. 2010; 9:3.
33. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ and Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010; 465(7301):1033-1038.
34. Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Laird PW, Jones PA and Liang G. Unique DNA methylation patterns distinguish superficial and invasive bladder cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010; 70: 8169-8178.
35. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D and Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature genetics 2011; 43(1):27-33.
36. DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D and Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PloS one. 2012; 7(5):e36669.
37. Hu Q, Luo Z, Xu T, Zhang JY, Zhu Y, Chen WX, Zhong SL, Zhao JH and Tang JH. FOXA1: a Promising Prognostic Marker in Breast Cancer. Asian Pacific journal of cancer prevention: APJCP. 2014; 15(1):11-16.
38. Robinson JL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, Papoutsoglou N, Neal DE, Tilley WD and Carroll JS. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPClike phenotype. Oncogene. 2013 Dec 2. doi: 10.1038/onc.2013.508
39. Powe DG, Dhondalay GK, Lemetre C, Allen T, Habashy HO, Ellis IO, Rees R and Ball GR. DACH1: its role as a classifier of long term good prognosis in luminal breast cancer. PloS one. 2014; 9(1):e84428.
40. Jin HJ, Zhao JC, Ogden I, Bergan RC and Yu J. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer research. 2013; 73(12):3725-3736.
41. Sahu B, Laakso M, Pihlajamaa P, Ovaska K, Sinielnikov I, Hautaniemi S and Janne OA. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer research. 2013; 73(5):1570-1580.
42. Catto JW and Rosario DJ. The road to cystectomy: who, when and why? Eur Urol: EAU Update series. 2005; 3(4):171-179.
43. Southgate J, Hutton KA, Thomas DF and Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest. 1994; 71(4):583-594.
44. Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE and Catto JW. Reduced expression of microRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Can Res. 2014; 20(7):1990-2000.
45. Tusher VG, Tibshirani R and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98(9):5116-5121.
46. Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS and Chen C. Real-time PCR quantification of precursor and mature microRNA. Methods (San Diego, Calif. 2008; 44(1):31-38.